Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2002 Nov;46(11):3627–3629. doi: 10.1128/AAC.46.11.3627-3629.2002

TEM-103/IRT-28 β-Lactamase, a New TEM Variant Produced by Escherichia coli BM4511

Rodrigo Alonso 1, Guy Gerbaud 1, Marc Galimand 1, Patrice Courvalin 1,*
PMCID: PMC128718  PMID: 12384377

Abstract

Clinical isolate Escherichia coli BM4511 was resistant to broad-spectrum penicillins in the presence or in the absence of β-lactamase inhibitors but remained susceptible to cephalosporins. Resistance was due to production of a new TEM-type β-lactamase, designated TEM-103/IRT-28, characterized by the Arg275Leu substitution and encoded by the ca. 62-kb pIP845 conjugative plasmid of the IncI1 incompatibility group.


Among the mechanisms responsible for resistance of Escherichia coli to β-lactam-β-lactamase inhibitor combinations, hyperproduction of TEM-1 penicillinase and alteration in the outer membrane proteins limiting the entry of the drugs were reported first (16, 19). Inhibitor-resistant TEM (IRT) β-lactamases have been isolated since the beginning of the 1990s and are mostly produced by strains of E. coli but also by clinical isolates of Klebsiella spp. and Proteus mirabilis (2). These enzymes confer resistance to penicillins and their combinations with β-lactamase inhibitors (3, 6, 13). IRT variants are derivatives of TEM β-lactamases, with mutations at various amino acid positions (69, 130, 244, 275, and 276, according to Ambler's numbering [1]) that have been shown, or postulated, to play a role in determining resistance to inhibitors. These substitutions decrease the affinity for β-lactams and alter the way in which the enzymes interact with suicide inactivators (9). We report the genetic characterization of a new TEM variant, TEM-103/IRT-28, in a clinical isolate of E. coli resistant to amoxicillin-clavulanate and susceptible to cephalosporins.

E. coli BM4511 was isolated from the surgery wound of an 82-year-old woman suffering from colon cancer and hospitalized in Hospital de Basurto, Bilbao, Spain. The MICs of various β-lactams, alone or in combination with β-lactamase inhibitors used at fixed concentrations (clavulanic acid, 2 μg/ml; tazobactam, 4 μg/ml; sulbactam, 8 μg/ml), were determined by the microdilution method in Mueller-Hinton broth (Difco) with an inoculum of approximately 5 × 104 cells/well. BM4511 was resistant to penicillins (MICs ≥ 1,024 μg/ml) but susceptible to cephalosporins (MICs ≤ 4 μg/ml). Clavulanic acid was unable to restore susceptibility of the strain to penicillins, but tazobactam reduced significantly the piperacillin MIC (Table 1). These data were compatible with the production of an IRT β-lactamase. The presence of a blaTEM gene in BM4511 was revealed by PCR amplification (data not shown) using primers TEM-C and TEM-H (12). To determine the pI of the enzyme, crude sonic bacterial extracts were applied to Phast-gels with different pH gradients in a Phast System (Pharmacia) and compared with TEM-30/IRT-2 (pI 5.2), TEM-1 (pI 5.4), and TEM-2 (pI 5.6). The strain was shown to produce a β-lactamase with an isoelectric point of 5.2 (data not shown). All IRT-type β-lactamases reported so far, except for TEM-59/IRT17 (pI 5.6), have a pI of either 5.2 or 5.4.

TABLE 1.

MICs of β-lactams against strains

E. coli strain MIC (μg/ml)a
AMX AMX + CLA TIC TIC + CLA AMP AMP + SUL PIP PIP + TZB CEF CFZ FOX
BM4511, blaTEM-103 >1,024 64 >1,024 64 >1,024 32 64 16 8 4 4
JM83 8 8 4 4 8 4 2 2 4 2 2
JM83 (pIP845), blaTEM-103 >1,024 32 >1,024 32 >1,024 32 64 8 8 4 4
TOP10 4 4 4 4 4 4 4 4 4 1 2
TOP10 (pAT779), blaTEM-103 >1,024 1,024 >1,024 >1,024 >1,024 >1,024 128 16 16 8 4
a

AMP, ampicillin; AMX, amoxicillin; CEF, cephalothin; CFZ, cefazolin; CLA, clavulanic acid (2 μg/ml); FOX, cefoxitin; PIP, piperacillin; SUL, sulbactam (8 μg/ml); TIC, ticarcillin; TZB, tazobactam (4 μg/ml).

Resistance to amoxicillin-clavulanate was transferred by conjugation from BM4511 to E. coli JM83 at an approximate frequency of 10−7 per donor. Analysis of the donor and of a transconjugant after digestion with EcoRI revealed the presence of a single plasmid, pIP845, with a size of approximately 62 kb. By reciprocal conjugation with E. coli BM21 (5) containing plasmids belonging to various incompatibility groups, pIP845 was found to be of incompatibility group I1; the size of these plasmids ranges between 55 and 80 kb (A. Labigne, personal communication).

Fragments of pIP845 DNA generated by double digestion with EcoRI and BamHI were inserted into pBGS18+ (17), and the resulting recombinant plasmids were introduced into E. coli TOP10 (Invitrogen) with selection on ampicillin at 100 μg/ml. The smallest plasmid able to confer resistance to amoxicillin-clavulanate to the new host, pAT779, had a 1.3-kb insert. Direct sequencing of the resistance gene, designated blaTEM-103, using an automated sequencer (CEQ 2000 DNA analysis system; Beckman Coulter) revealed that it was identical to blaTEM1-B except for a single G-to-T change at position 1020 (according to Sutcliffe's numbering [18]) (Table 2), which leads to the amino acid substitution of Arg to Leu at position 275 (according to Ambler's numbering [1]). The change of arginine, a basic positively charged amino acid, to leucine, an uncharged amino acid, accounts for the decrease in pI from 5.4 to 5.2 (9). Substitutions that lead to an inhibitor-resistant phenotype occur at a few specific sites within the TEM enzymes: Met-69, Arg-244, Arg-275, and Asn-276 (14). To the best of our knowledge, the Arg275Leu substitution has not yet been observed alone in TEM-type β-lactamases, and the enzyme was designated TEM-103/IRT-28 according to the TEM and IRT nomenclature (G. Jacoby and K. Bush, Amino acid sequences for TEM, SHV, and OXA extended-spectrum β-lactamases [http://www.lahey.org/studies/webt.html; last accessed 10 July 2002]).

TABLE 2.

Substitutions in blaTEM genes and derived β-lactamases

Region and nucleotide no.a (amino acid no.)b Nucleotide (amino acid) in the following gene (protein):
blaTEM-1A blaTEM-1B blaTEM-2 blaTEM-45 blaTEM-68 blaTEM-82 blaTEM-83 blaTEM-103
Promoter region P3 P3 Pa and Pb P4 Pa and Pb P4 P3
    32 C C T C NDd T C C
    162 G G G T ND G T G
    175 A G A A ND A A G
Coding region
    226c C (Phe) T C C T C C T
    317 (39) C (Gln) C A (Lys) C C C C C
    346c A (Glu) A G G A A G A
    407 (69) A (Met) A A A A G (Val) T (Ile) A
    409 (69) G (Met) G G T (Leu) G G G G
    436c C (Gly) T T T T C T T
    604c G (Ala) T G G G G G T
    682c T (Thr) T C C C T C T
    697 (165) G (Trp) G G ND G G T (Cys) G
    914 (238) G (Gly) G G ND A (Ser) G G G
    917 (240) G (Glu) G G ND A (Lys) G G G
    925c G (Gly) G A A A G A G
    929 (244) C (Arg) C C ND C C C C
    990 (265) C (Thr) C C ND T (Met) C C C
    1020 (275) G (Arg) G G A (Gln) T (Leu) A (Gln) A (Gln) T (Leu)
    1022 (276) A (Asn) A A ND A A A A
Source or reference 18 8 8 4 7 11 11 This study
a

Nucleotide numbering is according to J. G. Sutcliffe (18).

b

Amino acid numbering is according to Ambler et al. (1).

c

Positions at which only silent mutations occur.

d

ND, no data.

The Arg275Leu substitution has been detected in TEM-38/IRT-9 associated with Met69Val (9) and in TEM-68 associated with Gly238Ser, Glu240Lys, and Thr265Met (7). Another mutation at this position, Arg275Gln, was found in TEM-45/IRT-14 (4), TEM-82/IRT-24 (11), and TEM-83/IRT-25 (11) enzymes associated with Met69Leu, Met69Val, and Met69Ile substitutions, respectively; TEM-83 has, in addition, a Trp165Cys substitution. These β-lactamases, except for TEM-68, are enzymes with strong inhibitor-resistant activity because the Arg275 substitution is associated with substitutions at position 69 known to confer resistance to inhibitors (10). Therefore, the contribution of the Arg275 mutation to the IRT phenotype was not known.

Argnine 275 is located at the beginning of the C terminus of the α-11 helix, and its side chain is close to the guanidinium group of Arg244. A kinetic study of the Arg275Leu variant has shown the involvement of this change in resistance of the TEM β-lactamases to inactivation by clavulanic acid (15). This could be related to electrostatic interactions with Arg244 and/or to a possible displacement of the water molecule involved in the inactivation process of clavulanic acid (6). Variant TEM-68 (7) combines mutations responsible for the enlargement of the substrate profile (Gly238Ser, Glu240Lys, and Thr265Met) with a change (Arg275Leu) conferring resistance to inhibitors. Fiett et al. (7) attributed the inhibitor-resistant activity of TEM-68 to the Arg275Leu substitution.

Functional characterization of this new inhibitor-resistant β-lactamase should provide further insight into the understanding of the heterogeneity of IRT-type enzymes and into structure-activity relationships of the expanding family of TEM proteins.

Acknowledgments

We thank Ramón Cisterna for providing E. coli BM4511.

R. Alonso was the recipient of a postdoctoral grant from the Basque Government. This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases.

REFERENCES

  • 1.Ambler, R. P., A. F. Coulson, J. M. Frère, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276:269-270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bermudes, H., F. Jude, E. B. Chaibi, C. Arpin, C. Bebear, R. Labia, and C. Quentin. 1999. Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived β-lactamase in a clinical isolate of Klebsiella oxytoca. Antimicrob. Agents Chemother. 43:1657-1661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bonomo, R. A., S. A. Rudin, and D. M. Shlaes. 1997. Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases. FEMS Microbiol. Lett. 148:59-62. [DOI] [PubMed] [Google Scholar]
  • 4.Caniça, M. M., M. Barthélémy, L. Gilly, R. Labia, R. Krishnamoorthy, and G. Paul. 1997. Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type β-lactamases. Antimicrob. Agents Chemother. 41:374-378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chabbert, Y. A., M. R. Scavizzi, J. L. Witchitz, G. R. Gerbaud, and D. H. Bouanchaud. 1972. Incompatibility groups and the classification of fi resistance factors. J. Bacteriol. 112:666-675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chaibi, E. B., D. Sirot, G. Paul, and R. Labia. 1999. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother. 43:447-458. [DOI] [PubMed] [Google Scholar]
  • 7.Fiett, J., A. Palucha, B. Miaczynska, M. Stankiewicz, H. Przondo-Mordarska, W. Hryniewicz, and M. Gniadkowski. 2000. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing Klebsiellae. Antimicrob. Agents Chemother. 44:1499-1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Goussard, S., and P. Courvalin. 1999. Update sequence information for TEM β-lactamase genes. Antimicrob. Agents Chemother. 43:367-370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Henquell, C., C. Chanal, D. Sirot, R. Labia, and J. Sirot. 1995. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 39:427-430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Knox, J. R. 1995. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39:2593-2601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Leflon-Guibout, V., V. Speldooren, B. Heym, and M. H. Nicolas-Chanoine. 2000. Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of blaTEM genes. Antimicrob. Agents Chemother. 44:2709-2714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mabilat, C., and P. Courvalin. 1990. Development of oligotyping for characterization and molecular epidemiology of TEM β-lactamases in members of the family Enterobacteriaceae. Antimicrob. Agents Chemother. 34:2210-2216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Medeiros, A. A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24(Suppl. 1):S19-S45. [DOI] [PubMed] [Google Scholar]
  • 14.Nicolas-Chanoine, M. H. 1997. Inhibitor-resistant β-lactamases. J. Antimicrob. Chemother. 40:1-3. [DOI] [PubMed] [Google Scholar]
  • 15.Saves, I. 1995. Evolution de la β-lactamase TEM-1. Ph.D. thesis. University of Toulouse, Toulouse, France.
  • 16.Speldooren, V., B. Heym, R. Labia, and M. H. Nicolas-Chanoine. 1998. Discriminatory detection of inhibitor-resistant β-lactamases in Escherichia coli by single-strand conformation polymorphism-PCR. Antimicrob. Agents Chemother. 42:879-884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Spratt, B. G., P. J. Hedge, S. Heesen, A. Edelman, and J. K. Broome-Smith. 1986. Kanamycin-resistant vectors that are analogous of plasmids pUC8, pUC9, pEMBL8, and pEMBL9. Gene 41:337-342. [DOI] [PubMed] [Google Scholar]
  • 18.Sutcliffe, J. G. 1978. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc. Natl. Acad. Sci. USA 75:3737-3741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wu, P. J., K. Shannon, and I. Phillips. 1994. Effect of hyperproduction of TEM-1 β-lactamase on in vitro susceptibility of Escherichia coli to β-lactam antibiotics. Antimicrob. Agents Chemother. 38:494-498. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES